1. Tesaglitazar.
- Author
-
Kamber N and Davis TM
- Subjects
- Alkanesulfonates chemical synthesis, Alkanesulfonates metabolism, Alkanesulfonates pharmacology, Animals, Clinical Trials as Topic, Humans, Patents as Topic, Phenylpropionates chemical synthesis, Phenylpropionates metabolism, Phenylpropionates pharmacology, Structure-Activity Relationship, Alkanesulfonates therapeutic use, PPAR alpha agonists, PPAR gamma agonists, Phenylpropionates therapeutic use
- Abstract
AstraZeneca plc is developing tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, for the potential improvement of dyslipidemia and glycemic control in type 2 diabetic patients.
- Published
- 2005